CN112368282B - 氮杂苯并咪唑化合物和医药 - Google Patents
氮杂苯并咪唑化合物和医药 Download PDFInfo
- Publication number
- CN112368282B CN112368282B CN201980046177.6A CN201980046177A CN112368282B CN 112368282 B CN112368282 B CN 112368282B CN 201980046177 A CN201980046177 A CN 201980046177A CN 112368282 B CN112368282 B CN 112368282B
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyridin
- trifluoromethyl
- imidazo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018089867 | 2018-05-08 | ||
| JP2018-089867 | 2018-05-08 | ||
| PCT/JP2019/018201 WO2019216294A1 (ja) | 2018-05-08 | 2019-05-07 | アザベンゾイミダゾール化合物及び医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112368282A CN112368282A (zh) | 2021-02-12 |
| CN112368282B true CN112368282B (zh) | 2023-10-13 |
Family
ID=68467433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980046177.6A Active CN112368282B (zh) | 2018-05-08 | 2019-05-07 | 氮杂苯并咪唑化合物和医药 |
Country Status (35)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| BR112022008571A2 (pt) | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
| WO2021095805A1 (ja) * | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤 |
| CN118045050B (zh) * | 2023-11-16 | 2025-06-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法 |
| WO2025153078A1 (zh) * | 2024-01-17 | 2025-07-24 | 盛睿泽华医药科技（苏州）有限公司 | 可溶性环氧水解酶抑制剂及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039297A1 (en) * | 2005-10-06 | 2007-04-12 | Laboratorios Almirall, S.A. | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| WO2009092764A1 (en) * | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| JP2012031152A (ja) * | 2010-06-28 | 2012-02-16 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物からなる医薬 |
| WO2012080230A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080236A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2014128465A1 (en) * | 2013-02-20 | 2014-08-28 | Cancer Therapeutics Crc Pty Ltd | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| TW200538095A (en) | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1723142A1 (en) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| PT2054405E (pt) | 2006-07-11 | 2013-12-24 | Dae Woong Pharma | Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| WO2010130392A1 (de) | 2009-05-11 | 2010-11-18 | Ratiopharm Gmbh | Desfesoterodin in form eines weinsäuresalzes |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP6038150B2 (ja) | 2011-08-24 | 2016-12-07 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎｅｄｄ８活性化酵素阻害剤 |
| JP2013237634A (ja) | 2012-05-14 | 2013-11-28 | Dainippon Sumitomo Pharma Co Ltd | 縮環イミダゾロン誘導体 |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| EA031866B1 (ru) | 2014-06-06 | 2019-03-29 | Астеллас Фарма Инк. | Производное 2-ациламинотиазола или его соль |
| BR112017003901A2 (pt) | 2014-08-26 | 2017-12-12 | Astellas Pharma Inc | derivado de 2-aminotiazola ou sal do mesmo |
| JP6680297B2 (ja) | 2015-04-28 | 2020-04-15 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| CN115504986B (zh) | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| CA3085745A1 (en) | 2017-12-21 | 2019-06-27 | Kyorin Pharmaceutical Co., Ltd. | An agent for treating nocturnal pollakiuria |
| WO2019189766A1 (ja) | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2021095805A1 (ja) | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤 |
| BR112022008571A2 (pt) | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
-
2019
- 2019-05-07 ES ES19800286T patent/ES2992256T3/es active Active
- 2019-05-07 FI FIEP19800286.7T patent/FI3792260T3/fi active
- 2019-05-07 CA CA3099655A patent/CA3099655A1/en active Pending
- 2019-05-07 MD MDE20210245T patent/MD3792260T2/ro active IP Right Revival
- 2019-05-07 MY MYPI2020005795A patent/MY202833A/en unknown
- 2019-05-07 US US17/053,380 patent/US12319683B2/en active Active
- 2019-05-07 MX MX2020011855A patent/MX2020011855A/es unknown
- 2019-05-07 CN CN201980046177.6A patent/CN112368282B/zh active Active
- 2019-05-07 HR HRP20241414TT patent/HRP20241414T1/hr unknown
- 2019-05-07 WO PCT/JP2019/018201 patent/WO2019216294A1/ja not_active Ceased
- 2019-05-07 AU AU2019265134A patent/AU2019265134B2/en active Active
- 2019-05-07 SI SI201930830T patent/SI3792260T1/sl unknown
- 2019-05-07 SM SM20240407T patent/SMT202400407T1/it unknown
- 2019-05-07 EP EP19800286.7A patent/EP3792260B1/en active Active
- 2019-05-07 SG SG11202011003TA patent/SG11202011003TA/en unknown
- 2019-05-07 JP JP2020518289A patent/JP7235047B2/ja active Active
- 2019-05-07 PE PE2020001816A patent/PE20211384A1/es unknown
- 2019-05-07 KR KR1020207035176A patent/KR102819951B1/ko active Active
- 2019-05-07 HU HUE19800286A patent/HUE068695T2/hu unknown
- 2019-05-07 RS RS20241035A patent/RS65996B1/sr unknown
- 2019-05-07 PT PT198002867T patent/PT3792260T/pt unknown
- 2019-05-07 MA MA52587A patent/MA52587B1/fr unknown
- 2019-05-07 BR BR112020022662-9A patent/BR112020022662A2/pt unknown
- 2019-05-07 PL PL19800286.7T patent/PL3792260T3/pl unknown
- 2019-05-07 UA UAA202007681A patent/UA126774C2/uk unknown
- 2019-05-07 DK DK19800286.7T patent/DK3792260T3/da active
- 2019-05-07 IL IL278517A patent/IL278517B2/en unknown
- 2019-05-07 LT LTEPPCT/JP2019/018201T patent/LT3792260T/lt unknown
- 2019-05-08 TW TW108115846A patent/TWI868068B/zh active
-
2020
- 2020-11-05 CL CL2020002868A patent/CL2020002868A1/es unknown
- 2020-11-05 CO CONC2020/0013848A patent/CO2020013848A2/es unknown
- 2020-11-05 PH PH12020551873A patent/PH12020551873A1/en unknown
- 2020-11-05 SA SA520420487A patent/SA520420487B1/ar unknown
- 2020-11-17 ZA ZA2020/07164A patent/ZA202007164B/en unknown
- 2020-12-07 EC ECSENADI202078586A patent/ECSP20078586A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039297A1 (en) * | 2005-10-06 | 2007-04-12 | Laboratorios Almirall, S.A. | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| WO2009092764A1 (en) * | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| JP2012031152A (ja) * | 2010-06-28 | 2012-02-16 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物からなる医薬 |
| WO2012080230A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080236A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2014128465A1 (en) * | 2013-02-20 | 2014-08-28 | Cancer Therapeutics Crc Pty Ltd | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase |
Non-Patent Citations (3)
| Title |
|---|
| Long-acting muscarinic M3 receptor antagonists;Peter Norman;《Expert Opin. Ther. Patents》;20061231;第16卷(第9期);全文 * |
| Novel, highly selective, muscarinic M3 receptor antagonists;Banyu Pharm Co Ltd;《Expert Opin. Ther. Patengs》;20011231;第11卷(第9期);全文 * |
| Synthesis and optimization of novel and elective muscarinic M3 receptor antagonists;Naresh Kumar等;《Bioorganic & Medicinal Chemistry Letters》;20070630(第17期);全文 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112368282B (zh) | 氮杂苯并咪唑化合物和医药 | |
| BR112016008359B1 (pt) | Compostos de quinolina seletivamente substituídos, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para tratar lúpus eritematoso sistêmico, lúpus cutâneo, lúpus neuropsiquiátrico ou lúpus | |
| CN111819176A (zh) | 4-氮杂吲哚化合物 | |
| WO2023284703A1 (zh) | 基于布鲁顿酪氨酸激酶配体设计的蛋白降解化合物及其应用 | |
| KR102951288B1 (ko) | 아자벤즈이미다졸 화합물 및 의약 | |
| KR20220101142A (ko) | 기능성 소화관 장애 및 구강 건조증의 치료제 및 예방제 | |
| AU2018276190A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| KR20260010406A (ko) | Irak4의 리간드 지정 분해제로서의 헤테로아릴 화합물 | |
| HK40045733B (zh) | 氮杂苯并咪唑化合物和医药 | |
| HK40045733A (en) | Azabenzimidazole compounds and pharmaceutical | |
| RU2804485C2 (ru) | Азабензимидазольные соединения и фармкомпозиция | |
| HK40046611A (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40046611B (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40075503A (en) | Azabenzimidazole compound and medicine | |
| HK40081684A (en) | Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia | |
| WO2026002044A1 (zh) | 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用 | |
| HK40076325A (en) | Azabenzimidazole compound and medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40045733 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |